NM Physician's Notes · ¹⁷⁷Lu-PSMA-617
Each card opens a focused post on one aspect of running ¹⁷⁷Lu-PSMA-617 in an Indian centre — VISION + PSMAfore positioning across the mCRPC line of therapy, PSMA PET as the decision document, and the salivary-gland and kidney dose ceilings that bound the six-cycle course.
Lu-177 + PSMA-617
Posts in this section. New ones land here as they're added.
VISION eligibility, the PSMAfore line-of-therapy shift, and the salivary-gland and kidney dose ceilings that bound the six-cycle ¹⁷⁷Lu-PSMA-617 course.
Read this ChemistryThe salivary-gland dose ceiling, not tumour response, sets the six-cycle stopping criterion. Why ≥ 3,000 GBq/mg, ≥ 99.9 % RNP and ≥ 99 % RCP are what the VISION protocol chemistry actually requires.
Read thisWhere next